Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia

Vaccine

Volumn 33, Issue 46, 2015, Pages 6149-6151

  Regan, Annette K ^a,b   Tracey, Lauren ^b   Gibbs, Robyn ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Health Department of Western Australia   (Australia)

Author keywords

Inactivated quadrivalent influenza vaccine; Influenza vaccine; Public health surveillance; Vaccination; Vaccine safety

Indexed keywords

INFLUENZA VACCINE; INACTIVATED VACCINE;

ARTHRALGIA; ARTICLE; AUSTRALIA; DRUG SAFETY; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; IMMUNIZATION; INFLUENZA; INFLUENZA VACCINATION; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RIGOR; VACCINATION; ADULT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EDEMA; FEMALE; MALE; MIDDLE AGED; PAIN; PATHOLOGY; SKIN DISEASES; WESTERN AUSTRALIA;

ADULT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EDEMA; FEMALE; HEALTH PERSONNEL; HUMANS; INFLUENZA VACCINES; MALE; MIDDLE AGED; PAIN; PRODUCT SURVEILLANCE, POSTMARKETING; SKIN DISEASES; VACCINES, INACTIVATED; WESTERN AUSTRALIA;

EID: 84946605990     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.10.005     Document Type: Article

References (16)

1. Influenza vaccines: WHO position paper. Wkly Epidemiol Rec 2005, 33:279-287. World Health Organisation.
2. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. J Am Med Assoc 2003, 289(2):179-186.
3. Hite L.K., Glezen W.P., Demmler G.J., Munoz F.M. Medically attended pediatric influenza during the resurgence of the Victoria lineage of influenza B virus. Int J Infect Dis 2007, 11(1):40-47.
4. Kieninger D., Sheldon E., Lin W.Y., Yu C.J., Bayas J.M., Gabor J.J., et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. BMC Infect Dis 2013, 13:343.
5. Pepin S., Donazzolo Y., Jambrecina A., Salamand C., Saville M. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine 2013, 31(47):5572-5578.
6. Greenberg D.P., Roberston C.A., Noss M.J., Blatter M.M., Biedenbender R., Decker M.D. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013, 31(5):770-776.
7. Beran J., Peeters M., Dewé W., Raupachová J., Hobzová L., Devaster J.M. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis 2013, 13:224.
8. Tinoco J.C., Pavia-Ruz N., Cruz-Valdez A., Aranza Doniz C., Chandrasekaran V., Dewé W., et al. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial. Vaccine 2014, 32(13):1480-1487.
9. Greenberg D.P., Roberston C.A., Landolfi V.A., Bhaumik A., Senders S.D., Decker M.D. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. Pediatr Infect Dis J 2014, 33(6):630-636.
10. Domachowske J.B., Pankow-Culot H., Bautista M., Feng Y., Claeys C., Peeters M., et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013, 207(12):1878-1887.
11. Rodriguez Weber M.A., Claeys C., Aranza Doniz C., Feng Y., Innis B.L., Jain V.K., et al. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age. Pediatr Infect Dis J 2014, 33(12):1262-1269.
12. Haber P., Moro P.L., Cano M., Lewis P., Stewart B., Shimabukuro T.T. Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014. Vaccine 2015, 33(16):1987-1992.
13. Tracey L.E., Regan A.K., Mak D.B., Effler P.V. Adverse events following influenza immunization reported by healthcare personnel using active surveillance based on text messages. Infect Control Hosp Epidemiol 2015, 36(5):608-610.
14. Western Australia Department of Health. Western Australia Vaccine Safety Surveillance. Available at: (accessed 10.08.15). http://www.health.wa.gov.au/vaccination/wavss.cfm.
15. Lee B.Y., Bartsch S.M., Willig A.M. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012, 30(52):7443-7446.
16. Reed C., Meltzer M.I., Finelli L., Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012, 30(11):1993-1998.